Cargando…

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib

Recently tumor necrosis factor receptor super family member 18 (TNFRSF18, also called GITR) has been identified as a novel tumor suppressor gene in Multiple Myeloma (MM), undergoing aberrant DNA methylation-mediated gene expression silencing. Furthermore, the expression of GITR blocks canonical NF-κ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Yinghao, Zhang, Kun, Li, Guangquan, Zhang, Xingyi, Shi, Donglei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431824/ https://www.ncbi.nlm.nih.gov/pubmed/25973846 http://dx.doi.org/10.1371/journal.pone.0127334

Ejemplares similares

Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis
por: Zhang, Zhaoyuan, et al.
Publicado: (2020)

TRIM21 enhances bortezomib sensitivity in multiple myeloma by halting prosurvival autophagy
por: Chen, Jing, et al.
Publicado: (2023)

Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma
por: Liu, Yang, et al.
Publicado: (2013)

β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment
por: Santoni, Giorgio, et al.
Publicado: (2022)

Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib
por: Sanchez, W Y, et al.
Publicado: (2013)

PHLPP Sensitizes Multiple Myeloma Cells to Bortezomib Through Regulating LAMP2
por: Liu, Xiao, et al.
Publicado: (2020)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model
por: Kim, Chulwon, et al.
Publicado: (2019)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma
por: Huang, Xi, et al.
Publicado: (2022)

Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma
por: Hu, Xiaotong, et al.
Publicado: (2014)

ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy
por: Zhang, Huimin, et al.
Publicado: (2018)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
por: Di Lernia, Giuseppe, et al.
Publicado: (2020)

Entinostat-Bortezomib Hybrids against Multiple Myeloma
por: Ferro, Angelica, et al.
Publicado: (2023)

Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma
por: Roy, Mridul, et al.
Publicado: (2016)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA
por: MA, Naya, et al.
Publicado: (2023)

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells
por: Starheim, K K, et al.
Publicado: (2016)

Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells
por: Xu, Dehui, et al.
Publicado: (2019)

Solamargine induces autophagy‐mediated apoptosis and enhances bortezomib activity in multiple myeloma
por: Han, Qiaoyan, et al.
Publicado: (2022)

MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase
por: Rodrigues-Junior, Dorival Mendes, et al.
Publicado: (2021)

Bortezomib: the evidence of its clinical impact in multiple myeloma
por: Lancaster, Simon
Publicado: (2006)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
por: Petrucci, Maria Teresa, et al.
Publicado: (2014)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Tumor lysis syndrome in multiple myeloma treated with bortezomib
por: Dhanraj, K. M., et al.
Publicado: (2014)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2017)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bortezomib-Induced Reticular Eruption in Patient with Multiple Myeloma
por: Han, Joseph, et al.
Publicado: (2023)

CD8(+) T Cells: GITR Matters
por: Ronchetti, Simona, et al.
Publicado: (2012)

Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma
por: Li, Xuesong, et al.
Publicado: (2020)

Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells
por: Yao, Yao, et al.
Publicado: (2016)

The combination of ionizing radiation and proteasomal inhibition by bortezomib enhances the expression of NKG2D ligands in multiple myeloma cells
por: Lee, Young Shin, et al.
Publicado: (2018)

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
por: Chan, Sarah, et al.
Publicado: (2022)

Targeting MAGE-C1/CT7 Expression Increases Cell Sensitivity to the Proteasome Inhibitor Bortezomib in Multiple Myeloma Cell Lines
por: de Carvalho, Fabricio, et al.
Publicado: (2011)

GITR ligation enhances functionality of tumor‐infiltrating T cells in hepatocellular carcinoma
por: van Beek, Adriaan A., et al.
Publicado: (2019)

A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe
por: Hu, Liangning, et al.
Publicado: (2020)

Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma
por: Chen, Runzhe, et al.
Publicado: (2017)

BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis
por: Li, Guang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8vh7joq96poc9l7eaj8d4sgcjg